Nuvation Bio Quarterly Income Statement
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nuvation Bio revenue and earnings
In the quarter ended Jun 30, 2026, Nuvation Bio generated $31.7 million in revenue, up 555.6% from the same quarter a year earlier. Nuvation Bio reported a net loss of $62.8 million, compared with a loss of $59.0 million a year earlier. Operating margin was -161.1%.
Diluted earnings per share came in at -$0.18.
Summary generated from market data by MetaCap's automated system. Methodology
Nuvation Bio income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.69M | 83.23M | 41.87M | 13.12M | 4.83M | 3.08M | 5.71M | 727.00K | 1.44M | 0 | 0 | 0 |
| Revenue growth (YoY) | +555.64% | +2598.70% | +633.06% | +1704.68% | +236.79% | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | 3.35M | 2.58M | 2.09M | 4.22M | 1.51M | 1.35M | 0 | — | — |
| Gross Profit | — | — | — | 9.77M | 2.26M | 990.00K | 1.50M | -788.00K | 88.00K | 0 | 0 | 0 |
| Operating Expenses | 82.72M | 79.35M | 83.92M | 66.20M | 68.42M | 62.09M | 62.52M | 47.31M | 470.47M | 20.20M | 20.83M | 26.34M |
| Research & Development | 30.66M | 35.05M | 34.30M | 28.85M | 27.36M | 24.60M | 29.30M | 27.73M | 29.25M | 12.84M | 15.35M | 18.56M |
| Selling, General & Admin | 42.59M | 38.31M | 40.33M | 37.36M | 38.48M | 35.39M | 26.14M | 19.58M | 16.16M | 7.36M | 5.48M | 7.78M |
| Operating Income | -51.04M | 3.88M | -34.04M | -56.43M | -63.59M | -59.00M | -53.94M | -48.10M | -470.38M | -20.20M | -20.83M | -26.34M |
| Interest Expense | 6.76M | 6.71M | 6.67M | 5.12M | 421.00K | 54.00K | 89.00K | 120.00K | 132.00K | 0 | 0 | 0 |
| Other Income (Expense) | -11.80M | 1.52M | -2.56M | 642.00K | 4.58M | 5.77M | 4.50M | 6.89M | 7.89M | 5.41M | 7.04M | 6.69M |
| Pretax Income | -62.84M | 5.40M | -36.59M | -55.79M | -59.01M | -53.24M | -49.45M | -41.21M | -462.49M | -14.79M | -13.79M | -19.65M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -62.84M | 5.40M | -36.59M | -55.79M | -59.01M | -53.24M | -49.45M | -41.21M | -462.49M | -14.79M | -13.79M | -19.65M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.18 | 0.02 | -0.11 | -0.16 | -0.17 | -0.16 | 0.00 | -0.15 | -1.89 | -0.07 | -0.07 | -0.09 |
| EPS (Diluted) | -0.18 | 0.01 | -0.11 | -0.16 | -0.17 | -0.16 | 0.00 | -0.15 | -1.89 | -0.07 | -0.07 | -0.09 |
| Shares Outstanding (Basic) | 348.77K | 347.33K | — | 342.39K | 340.75K | 338.61K | — | 273.56K | 244.74K | 219.05K | — | 218.94K |
| Shares Outstanding (Diluted) | 348.77K | 377.52K | — | 342.39K | 340.75K | 338.61K | — | 273.56K | 244.74K | 219.05K | — | 218.94K |
| EBITDA | -50.50M | 4.42M | -33.50M | -55.90M | -63.23M | -58.69M | -53.72M | -47.94M | -470.14M | -20.14M | -20.78M | -26.28M |
| Gross Margin | — | — | — | 74.47% | 46.70% | 32.10% | 26.18% | -108.39% | 6.13% | — | — | — |
| Operating Margin | -161.06% | 4.66% | -81.30% | -430.14% | -1315.73% | -1913.23% | -944.53% | -6616.37% | -32779.44% | — | — | — |
| Net Margin | -198.31% | 6.48% | -87.40% | -425.24% | -1220.92% | -1726.20% | -865.79% | -5668.50% | -32229.41% | — | — | — |
This table shows 12 quarterly periods of Nuvation Bio's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NUVB's reporting calendar. What is a income statement?